Key Stats for CVS Health Stock
- Price change for CVS Health stock: 3%
- $CVS Share Price as of Jun. 22: $101
- 52-Week High: $103
- $CVS Stock Price Target: $105
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
CVS Health (CVS) stock hit a fresh 52-week high today, touching $102.78 intraday before pulling back slightly. Shares are up around 3% on the back of two catalysts: a strong Q1 earnings beat and the launch of a new integrated GLP-1 support program that’s drawing attention from Wall Street.
On the earnings front, CVS delivered adjusted EPS of $2.57 in Q1, up 14% year-over-year.
- Total revenue exceeded $100 billion.
- The Health Care Benefits segment led the way, with adjusted operating income of approximately $3 billion — a major year-over-year improvement as Aetna continues to recover toward target margins.
- The company raised its full-year adjusted EPS guidance to $7.30 – $7.50, up from the prior range of $7.00 – $7.20.
- The bigger headline driving CVS Health stock today is the expansion of its GLP-1 program.
- CVS is rolling out integrated weight-loss drug support across its 9,000 pharmacy locations, MinuteClinic, and its virtual healthcare platform.
- The program includes a $50-per-month Medicare Bridge offering and commercial pricing as low as $25 per month.
- CVS will also participate in the CMS Medicare GLP-1 Bridge program starting July 1, 2026.
Bank of America analyst Allen Lutz raised his price target to $110 from $100 in response. His note pointed out that retail pharmacies have been slow to respond to the rapid growth of online GLP-1 pharmacies. CVS’s advantage is that it can deliver these programs at competitive prices while leveraging infrastructure that online-only players simply don’t have.
CVS also updated its commercial formularies to make Zepbound a preferred GLP-1 option and removed the new-to-market block on Foundayo. Same-store pharmacy sales grew 3% in Q1, with prescription volumes up nearly 7% year-over-year.
See analysts’ growth forecasts and price targets for CVS Health stock (It’s free) >>>
What the Market Is Telling Us About CVS Health Stock
CVS Health stock has gained 52% over the past year. Today’s move adds to that momentum.
With GLP-1 demand surging and online pharmacies capturing market share, today’s program launch signals CVS is done waiting on the sidelines.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does CVS Health Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
